Zusammenfassung
Interventionen bei aggressivem Verhalten psychisch erkrankter Menschen erfolgen grundsätzlich in zwei Intentionen: zum Zweck der Behandlung und zum Zweck der Sicherung bzw. Gefahrenabwehr.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Notes
- 1.
Haloperidol soll laut der aktuellen Fachinfo nicht mit anderen QTc-Zeit verlängernden Medikamenten verabreicht werden, wozu auch Promethazin und Biperiden gehören.
Literatur
Kapitel 10
Acharya D, Harper DG, Achtyes ED, Seiner SJ, Mahdasian JA, Nykamp LJ et al (2015) Safety and utility of acute electroconvulsive therapy for agitation and aggression in dementia. Int J Geriatr Psychiatr 30(3):265–273. https://doi.org/10.1002/gps.4137
Aichele Valentin (2013) Einleitung. In: Aichele Valentin, Deutsches Institut für Menschenrechte (Hrsg) Das Menschenrecht auf gleiche Recht auf Anerkennung vor dem Recht. Art. 12 der UN-Behindertenrechtskonvention. Nomos, Baden-Baden, S 13–34
Albrecht B, Staiger PK, Hall K, Miller P, Best D, Lubman DI (2014) Benzodiazepine use and aggressive behaviour: a systematic review. Aust N Z J Psychiatr 48(12):1096–1114. https://doi.org/10.1177/0004867414548902
Alexander J, Tharyan P, Adams C, John T, Mol C, Philip J (2004) Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting. Pragmatic randomised trial of intramuscular lorazepam v. haloperidol plus promethazine. Br J Psychiatry J Ment Sci 185:63–69
Ali A, Hall I, Blickwedel J, Hassiotis A (2015) Behavioural and cognitive-behavioural interventions for outwardly-directed aggressive behaviour in people with intellectual disabilities. Cochrane Database Syst Rev (4):CD003406. https://doi.org/10.1002/14651858.CD003406.pub4
Allen MH, Currier GW (2004) Use of restraints and pharmacotherapy in academic psychiatric emergency services. Gen Hosp Psychiatry 26(1):42–49
Allen MH, Feifel D, Lesem MD, Zimbroff DL, Ross R, Munzar P et al (2011) Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatr 72(10):1313–1321. https://doi.org/10.4088/JCP.10m06011yel
Aman M, Rettiganti M, Nagaraja HN, Hollway JA, McCracken J, McDougle CJ et al (2015) Tolerability, safety, and benefits of risperidone in children and adolescents with autism: 21-month follow-up after 8-week placebo-controlled trial. J Child Adolesc Psychopharmacol 25(6):482–493. https://doi.org/10.1089/cap.2015.0005
Andrezina R, Josiassen RC, Marcus RN, Oren DA, Manos G, Stock E et al (2006) Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology 188(3):281–292. https://doi.org/10.1007/s00213-006-0541-x
Arango C, Bernardo M (2005) The effect of quetiapine on aggression and hostility in patients with schizophrenia. Hum Psychopharmacol 20(4):237–241. https://doi.org/10.1002/hup.686
Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (2018) S3-Leitlinie „Screening, Diagnose und Behandlung alkoholbezogener Störungen“. http://www.awmf.org/uploads/tx_szleitlinien/076-001l_S3-Leitlinie_Alkohol_2016-02.pdf. Zugegriffen am 20.03.2018
Aupperle P (2006) Management of aggression, agitation, and psychosis in dementia: focus on atypical antipsychotics. Am J Alzheimers Dis Other Dement 21(2):101–108. https://doi.org/10.1177/153331750602100209
Baldacara L, Sanches M, Cordeiro DC, Jackoswski AP (2011) Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone. Rev Bras Psiquiatr (Sao Paulo) 33(1):30–39
Ballard C, Waite J (2006) The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev (1):CD003476. https://doi.org/10.1002/14651858.CD003476.pub2
Ballard C, Corbett A, Chitramohan R, Aarsland D (2009) Management of agitation and aggression associated with Alzheimer’s disease: controversies and possible solutions. Curr Opin Psychiatr 22(6):532–540. https://doi.org/10.1097/YCO.0b013e32833111f9
Ballard C, Creese B, Corbett A, Aarsland D (2011) Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality. Expert Opin Drug Saf 10(1):35–43. https://doi.org/10.1517/14740338.2010.506711
Banerjee S (2009) The use of antipsychotic medication for people with dementia: time for action. A report for the minister of state for care services by Professor Sube Banerjee. http://psychrights.org/research/digest/nlps/banerjeereportongeriatricneurolepticuse.pdf
Baruch N, Das M, Sharda A, Basu A, Bajorek T, Ross CC et al (2014) An evaluation of the use of olanzapine pamoate depot injection in seriously violent men with schizophrenia in a UK high-security hospital. Therapeut Adv Psychopharmacol 4(5):186–192. https://doi.org/10.1177/2045125314531982
Battaglia J, Moss S, Rush J, Kang J, Mendoza R, Leedom L et al (1997) Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg Med 15(4):335–340
Belgamwar RB, Fenton M (2005) Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses. Cochrane Database Syst Rev (2):CD003729. https://doi.org/10.1002/14651858.CD003729.pub2
Bellino S, Paradiso E, Bozzatello P, Bogetto F (2010) Efficacy and tolerability of duloxetine in the treatment of patients with borderline personality disorder: a pilot study. J Psychopharmacol (Oxford) 24(3):333–339. https://doi.org/10.1177/0269881108095715
Bellino S, Bozzatello P, Rocca G, Bogetto F (2014) Efficacy of omega-3 fatty acids in the treatment of borderline personality disorder: a study of the association with valproic acid. J Psychopharmacol (Oxford) 28(2):125–132. https://doi.org/10.1177/0269881113510072
Bieniek SA, Ownby RL, Penalver A, Dominguez RA (1998) A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation. Pharmacotherapy 18(1):57–62
Bienwald W, Sonnenfeld S, Bienwald C, Harm U (2016) Betreuungsrecht. Kommentar,. § 1901a BGB, 6. Aufl. Gieseking, Bielefeld
Blair M, Moulton-Adelman F (2015) The engagement model for reducing seclusion and restraint: 13 years later. J Psychosoc Nurs Ment Health Serv 53(3):39–45. https://doi.org/10.3928/02793695-20150211-01
Bleijlevens MHC, Wagner LM, Capezuti E, Hamers JPH (2016) Physical restraints: consensus of a research definition using a modified Delphi technique. J Am Geriatr Soc 64(11):2307–2310. https://doi.org/10.1111/jgs.14435
Bolea-Alamanac BM, Davies SJC, Christmas DM, Baxter H, Cullum S, Nutt DJ (2011) Cyproterone to treat aggressivity in dementia: a clinical case and systematic review. J Psychopharmacol (Oxford) 25(1):141–145. https://doi.org/10.1177/0269881109353460
Bont L, Bosker HA, Brus F, Yska JP, Bosch FH (1998) Torsade de pointes after pipamperone intoxication. Pharm World Sci PWS 20(3):137
Bozeman WP, Ali K, Winslow JE (2013) Long QT syndrome unmasked in an adult subject presenting with excited delirium. J Emerg Med 44(2):e207–e210. https://doi.org/10.1016/j.jemermed.2012.02.054
Bozikas V, Bascialla F, Yulis P, Savvidou I, Karavatos A (2001) Gabapentin for behavioral dyscontrol with mental retardation. Am J Psychiatry 158(6):965–966. https://doi.org/10.1176/appi.ajp.158.6.965
Brink C (2010) Grenzen der Anstalt. Psychiatrie und Gesellschaft in Deutschland 1860–1980. Wallstein, Göttingen
Brophy LM, Roper CE, Hamilton BE, Tellez JJ, McSherry BM (2016) Erratum to: consumers and their supporters’ perspectives on poor practice and the use of seclusion and restraint in mental health settings: results from Australian focus groups. Int J Ment Heal Syst 10:7. https://doi.org/10.1186/s13033-016-0039-9
Brosey D (2010) Psychiatrische Patientenverfügung nach dem 3. Betreuungsänderungsgesetz, Wille und Behandlungswünsche bei psychiatrischer Behandlung und Unterbringung. Betreuungspraxis 19:161–167
Brown D, Larkin F, Sengupta S, Romero-Ureclay JL, Ross CC, Gupta N et al (2014) Clozapine: an effective treatment for seriously violent and psychopathic men with antisocial personality disorder in a UK high-security hospital. CNS spectrums 19(5):391–402. https://doi.org/10.1017/S1092852914000157
Caspi N, Modai I, Barak P, Waisbourd A, Zbarsky H, Hirschmann S, Ritsner M (2001) Pindolol augmentation in aggressive schizophrenic patients: a double-blind crossover randomized study. Int Clin Psychopharmacol 16(2):111–115
Citrome L (2007) Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. J Clin Psychiatr 68(12):1876–1885
Coccaro EF, Lee RJ, Kavoussi RJ (2009) A double-blind, randomized, placebo-controlled trial of fluoxetine in patients with intermittent explosive disorder. J Clin Psychiatr 70(5):653–662. https://doi.org/10.4088/JCP.08m04150
Comai S, Tau M, Gobbi G (2012) The psychopharmacology of aggressive behavior: a translational approach: part 1: neurobiology. J Clin Psychopharmacol 32(1):83–94. https://doi.org/10.1097/JCP.0b013e31823f8770
Comai S, Tau M, Pavlovic Z, Gobbi G (2012 Apr) The psychopharmacology of aggressive behavior: a translational approach: part 2: clinical studies using atypical antipsychotics, anticonvulsants, and lithium. J Clin Psychopharmacol 32(2):237–260. https://doi.org/10.1097/JCP.0b013e31824929d6
Convention on the Rights of Persons with Disabilities United Nations (Hrsg) (2014) General comment no. 1 (2014). Article 12: equal recognition before the law (CRPD/C/GC/!). http://daccess-dds-ny.un.org/doc/UNDOC/GEN/G14/031/20/PDF/G1403120.pdf
Cooney C, Mortimer A, Smith A, Newton K, Wrigley M (1996) Carbamazepine use in aggressive behaviour associated with senile dementia. Int J Geriatr Psychiatry 11:901–905
Cooney C, Murphy S, Tessema H, Freyne A (2013) Use of low-dose gabapentin for aggressive behavior in vascular and Mixed Vascular/Alzheimer Dementia. J Neuropsychiatr Clin Neurosci 25(2):120–125. https://doi.org/10.1176/appi.neuropsych.12050115
Craft M, Ismail IA, Krishnamurti D, Mathews J, Regan A, Seth RV, North PM (1987) Lithium in the treatment of aggression in mentally handicapped patients. A double-blind trial. Br J Psychiatry J Ment Sci 150:685–689
Cumbo E, Ligori LD (2014) Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer’s disease: a 12-month, randomized, open-label trial. J Alzheimers Disease JAD 39(3):477–485. https://doi.org/10.3233/JAD-131190
Currier GW, Chou JC-Y, Feifel D, Bossie CA, Turkoz I, Mahmoud RA, Gharabawi GM (2004) Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. J Clin Psychiatr 65(3):386–394
Dean BV, Stellpflug SJ, Burnett AM, Engebretsen KM (2013) 2C or not 2C: phenethylamine designer drug review. J Med Toxicol Off J Am College Med Toxicol 9(2):172–178. https://doi.org/10.1007/s13181-013-0295-x
Deb S, Farmah BK, Arshad E, Deb T, Roy M, Unwin GL (2014) The effectiveness of aripiprazole in the management of problem behaviour in people with intellectual disabilities, developmental disabilities and/or autistic spectrum disorder – a systematic review. Res Dev Disabil 35(3):711–725. https://doi.org/10.1016/j.ridd.2013.12.004
Declercq T, Petrovic M, Azermai M, Vander Stichele R, De Sutter AI, van Driel ML, Christiaens T (2013) Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev (3):CD007726. https://doi.org/10.1002/14651858.CD007726.pub2.
Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde – Taskforce Patientenautonomie (2016) Eckpunkte für die Regelung der öffentlich-rechtlichen Unterbringung in psychiatrischen Krankenhäusern – mit Erläuterungen. Nervenarzt 87:311–314
Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN) (2012a) Stellungnahme zum Urteil des Bundesverfassungsgerichts vom 23.03.2011 zur Zwangsbehandlung im Maßregelvollzug (Stellungnahme, 1)
Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN) (2012b) Memorandum zur Autonomie und Selbstbestimmung von Menschen mit psychischen Störungen (Stellungnahme, 15)
Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN) (2014) Achtung der Selbstbestimmung und Anwendung von Zwang bei der Behandlung psychisch erkrankter Menschen: Eine ethische Stellungnahme der DGPPN (2014). Nervenarzt 85(11):1419–1431. https://doi.org/10.1007/s00115-014-4202-8
Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN). (Hrsg) Ländersache: öffentlich-rechtliche Unterbringung in der Psychiatrie. https://www.dgppn.de/schwerpunkte/menschenrechte/uebersicht-psychKGs.html
Deutsche Gesellschaft für Soziale Psychiatrie e.V. (DGSP) (2012) Zwangsbehandlung in der Psychiatrie – Urteile und wie weiter … https://www.dgsp-ev.de/fileadmin/user_files/dgsp/pdfs/Stellungnahmen/Stellungnahme_Zwangsbehandlung_in_der_Psychiatrie_I.pdf. Zugegriffen am 20.02.2018
Devanand DP, Mintzer J, Schultz SK, Andrews HF, Sultzer DL, de La Pena D et al (2012) Relapse risk after discontinuation of risperidone in Alzheimer’s disease. N Engl J Med 367(16):1497–1507. https://doi.org/10.1056/NEJMoa1114058
Diener J (2013) Patientenverfügungen psychisch Kranker und fürsorglicher Zwang. Duncker & Humblot, Berlin
Dorevitch A, Katz N, Zemishlany Z, Aizenberg D, Weizman A (1999) Intramuscular flunitrazepam versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior. Am J Psychiatry 156(1):142–144. https://doi.org/10.1176/ajp.156.1.142
Dreßing H, Dreßing C (2013) Strafanzeige bei Gewalttätigkeit von psychisch Kranken während der stationären Behandlung – Pro & Kontra. Psychiatr Prax 40:11
van den Elsen GAH, Ahmed AIA, Verkes R-J, Kramers C, Feuth T, Rosenberg PB et al (2015) Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: a randomized controlled trial. Neurology 84(23):2338–2346. https://doi.org/10.1212/WNL.0000000000001675
Fakra E, Azorin J-M (2012) Clozapine for the treatment of schizophrenia. Expert Opin Pharmacother 13(13):1923–1935. https://doi.org/10.1517/14656566.2012.709235
Fanning JR, Berman ME, Guillot CR, Marsic A, McCloskey MS (2014) Serotonin (5-HT) augmentation reduces provoked aggression associated with primary psychopathy traits. J Personal Disord 28(3):449–461. https://doi.org/10.1521/pedi_2012_26_065
Fazel S, Zetterqvist J, Larsson H, Langstrom N, Lichtenstein P (2014) Antipsychotics, mood stabilisers, and risk of violent crime. Lancet (London) 384(9949):1206–1214. https://doi.org/10.1016/S0140-6736(14)60379-2
Felthous AR (2015) The appropriateness of treating psychopathic disorders. CNS Spectr 20(3):182–189. https://doi.org/10.1017/S1092852915000243
Fisher CA, Sewell K, Brown A, Churchyard A (2014) Aggression in Huntington’s disease: a systematic review of rates of aggression and treatment methods. J Huntingtons Dis 3(4):319–332. https://doi.org/10.3233/JHD-140127
Flo E, Gulla C, Husebo BS (2014) Effective pain management in patients with dementia: benefits beyond pain? Drugs Aging 31(12):863–871. https://doi.org/10.1007/s40266-014-0222-0
Foster S, Kessel J, Berman ME, Simpson GM (1997) Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. Int Clin Psychopharmacol 12(3):175–179
Fox C, Crugel M, Maidment I, Auestad BH, Coulton S, Treloar A et al (2012) Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double-blind placebo controlled trial. PLoS One 7(5):e35185. https://doi.org/10.1371/journal.pone.0035185
Frogley C, Taylor D, Dickens G, Picchioni M (2012) A systematic review of the evidence of clozapine’s anti-aggressive effects. Int J Neuropsychopharmacol 15(9):1351–1371. https://doi.org/10.1017/S146114571100201X
Gallagher D, Herrmann N (2014) Antiepileptic drugs for the treatment of agitation and aggression in dementia: do they have a place in therapy? Drugs 74(15):1747–1755. https://doi.org/10.1007/s40265-014-0293-6
Gareri P, Putignano D, Castagna A, Cotroneo AM, de Palo G, Fabbo A et al (2014) Retrospective study on the benefits of combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer’s disease: the MEMAGE study. J Alzheimers Dis JAD 41(2):633–640. https://doi.org/10.3233/JAD-132735
Garza-Trevino ES, Hollister LE, Overall JE, Alexander WF (1989) Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. Am J Psychiatry 146(12):1598–1601. https://doi.org/10.1176/ajp.146.12.1598
Gauthier S, Loft H, Cummings J (2008) Improvement in behavioural symptoms in patients with moderate to severe Alzheimer’s disease by memantine: a pooled data analysis. Int J Geriatr Psychiatr 23(5):537–545. https://doi.org/10.1002/gps.1949
Gillies D, Sampson S, Beck A, Rathbone J (2013) Benzodiazepines for psychosis-induced aggression or agitation. Cochrane Database Syst Rev (4):CD003079. https://doi.org/10.1002/14651858.CD003079.pub3
Gobbi G, Gaudreau P-O, Leblanc N (2006) Efficacy of topiramate, valproate, and their combination on aggression/agitation behavior in patients with psychosis. J Clin Psychopharmacol 26(5):467–473. https://doi.org/10.1097/01.jcp.0000237945.35022.45
Gobbi G, Comai S, Debonnel G (2014) Effects of quetiapine and olanzapine in patients with psychosis and violent behavior: a pilot randomized, open-label, comparative study. Neuropsychiatr Dis Treat 10:757–765. https://doi.org/10.2147/NDT.S59968
Gowin JL, Green CE, Alcorn JL, Swann AC, Moeller FG, Lane SD (2012) Chronic tiagabine administration and aggressive responding in individuals with a history of substance abuse and antisocial behavior. J Psychopharmacol (Oxford) 26(7):982–993. https://doi.org/10.1177/0269881111408962
Guay DRP (2007) Newer antiepileptic drugs in the management of agitation/aggression in patients with dementia or developmental disability. Consult Pharm J Am Soc Consult Pharm 22(12):1004–1034
Guinchat V, Cravero C, Diaz L, Perisse D, Xavier J, Amiet C et al (2015) Acute behavioral crises in psychiatric inpatients with autism spectrum disorder (ASD): recognition of concomitant medical or non-ASD psychiatric conditions predicts enhanced improvement. Res Dev Disabil 38:242–255. https://doi.org/10.1016/j.ridd.2014.12.020
Haessler F, Glaser T, Beneke M, Pap AF, Bodenschatz R, Reis O (2007) Zuclopenthixol in adults with intellectual disabilities and aggressive behaviours: discontinuation study. Br J Psychiatr J Mental Sci 190:447–448. https://doi.org/10.1192/bjp.bp.105.016535
Hassler F, Reis O (2010) Pharmacotherapy of disruptive behavior in mentally retarded subjects: a review of the current literature. Dev Disabil Res Rev 16(3):265–272. https://doi.org/10.1002/ddrr.119
Hassler F, Glaser T, Reis O (2011) Effects of zuclopenthixol on aggressive disruptive behavior in adults with mental retardation – a 2-year follow-up on a withdrawal study. Pharmacopsychiatry 44(7):339–343. https://doi.org/10.1055/s-0031-1291174
Henking T (2014) In: Henking T, Vollmann J (Hrsg) Gewalt und Psyche – Die Zwangsbehandlung auf dem Prüfstand. Nomos, Baden-Baden, S 103–121
Henking T (2016) Patientenrechte im Kontext von Zwang. Recht Psychiatrie
Henking T (2017) Das Konzept der offenen Türen – offen und doch geschlossen. Recht Psychiatrie 35:68–71
Henking T, Bruns H (2014a) Die Patientenverfügung in der Psychiatrie. Z Gesundheitsrecht 13:585–590
Henking T, Bruns H (2014b) Die Patientenverfügung in der Psychiatrie. Z Gesundheitsrecht 13:585–590
Henking T, Mittag M (2013) Die Zwangsbehandlung in der öffentlich-rechtlichen Unterbringung – Vorschlag einer Neuregelung. Juristische Rundschau 2013(8):341–351
Henking T, Mittag M (2014) Die Zwangsbehandlung in der öffentlich-rechtlichen Unterbringung – Stand der Neuregelungen. Betreuungsrechtliche Praxis 23(3):115–119
Henking T, Mittag M (2015) Rechtliche Rahmenbedingungen. In: Henking T, Vollmann J (Hrsg) Zwangsbehandlung psychisch kranker Menschen – Ein Leitfaden für die Praxis. Springer, Berlin
Henking, Tanja, Vollmann J (2014): Gewalt und Psyche – Die Zwangsbehandlung auf dem Prüfstand: Nomos, Baden-Baden
Henking T, Vollmann J (Hrsg) (2015) Zwangsbehandlung psychisch kranker Menschen – Ein Leitfaden für die Praxis. Springer, Berlin
Herrmann N, Lanctot KL (2007) Pharmacologic management of neuropsychiatric symptoms of Alzheimer disease. Can J Psychiatry 52(10):630–646. https://doi.org/10.1177/070674370705201004
Herrmann N, Gauthier S, Boneva N, Lemming OM (2013) A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer’s disease. Int Psychogeriatr 25(6):919–927
Hollander E, Tracy KA, Swann AC, Coccaro EF, McElroy SL, Wozniak P et al (2003) Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacol Off Publ Am College Neuropsychopharmacol 28(6):1186–1197. https://doi.org/10.1038/sj.npp.1300153
Honglin W (2005) Combination of magnesium valproate and anti-psychotics in aggressive behaviors of schizophrenics [J]. J Clin Psychosomatic Diseases 1:2
Hotham JE, Simpson PJD, Brooman-White RS, Basu A, Ross CC, Humphreys SA et al (2014) Augmentation of clozapine with amisulpride: an effective therapeutic strategy for violent treatment-resistant schizophrenia patients in a UK high-security hospital. CNS Spectr 19(5):403–410. https://doi.org/10.1017/S1092852913000874
Hsu WY, Huang SS, Lee BS, Chiu NY (2010) Comparison of intramuscular olanzapine, orally disintegrating olanzapine tablets, oral risperidone solution, and intramuscular haloperidol in the management of acute agitation in an acute care psychiatric ward in Taiwan. J Clin Psychopharmacol 30(3):230–234. https://doi.org/10.1097/JCP.0b013e3181db8715
Huang CL-C, Hwang T-J, Chen Y-H, Huang G-H, Hsieh MH, Chen H-H, Hwu H-G (2015) Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: an open-label, randomized controlled trial. J Formosan Med Assoc Taiwan yi zhi 114(5):438–445. https://doi.org/10.1016/j.jfma.2015.01.018
Huf G, Alexander J, Gandhi P, Allen MH (2016) Haloperidol plus promethazine for psychosis-induced aggression. Cochrane Database Syst Rev 11:CD005146. https://doi.org/10.1002/14651858.CD005146.pub3
Husebo BS, Ballard C, Sandvik R, Nilsen OB, Aarsland D (2011) Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial. BMJ (Clinical research ed.) 343:d4065. https://doi.org/10.1136/bmj.d4065
Im DS (2016) Template to perpetrate: an update on violence in autism spectrum disorder. Harvard Rev Psychiatr 24(1):14–35. https://doi.org/10.1097/HRP.0000000000000087
Iozzino L, Ferrari C, Large M, Nielssen O, de Girolamo G (2015) Prevalence and risk factors of violence by psychiatric acute inpatients: a systematic review and meta-analysis. PLoS One 10(6):e0128536. https://doi.org/10.1371/journal.pone.0128536
Jayakody K, Gibson RC, Kumar A, Gunadasa S (2012) Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses. Cochrane Database Syst Rev (4):CD000525. https://doi.org/10.1002/14651858.CD000525.pub3
Jones RM, Arlidge J, Gillham R, Reagu S, van den Bree M, Taylor PJ (2011) Efficacy of mood stabilisers in the treatment of impulsive or repetitive aggression: systematic review and meta-analysis. Br J Psychiatry J Ment Sci 198(2):93–98. https://doi.org/10.1192/bjp.bp.110.083030
de Jong MH, Kamperman AM, Oorschot M, Priebe S, Bramer W, van de Sande R et al (2016) Interventions to reduce compulsory psychiatric admissions: a systematic review and meta-analysis. JAMA psychiatr 73(7):657–664. https://doi.org/10.1001/jamapsychiatry.2016.0501
Jürgens A (2014) Betreuungsrecht, 5., völlig überarb. Aufl. C.H. BECK (Gelbe Erläuterungsbücher), München
Kaufman KR, Newman NB, Dawood A (2014) Capgras delusion with violent behavior in Alzheimer dementia: case analysis with literature review. Ann Clin Psychiatr Off J Am Acad Clin Psychiatr 26(3):187–191
Khalifa N, Duggan C, Stoffers J, Huband N, Vollm BA, Ferriter M, Lieb K (2010) Pharmacological interventions for antisocial personality disorder. Cochrane Database Syst Rev (8):CD007667. https://doi.org/10.1002/14651858.CD007667.pub2
King BH, Davanzo P (1996) Buspirone treatment of aggression and self-injury in autistic and nonautistic persons with severe mental retardation. Dev Brain Dysf
Kishi T, Matsunaga S, Iwata N (2015) Intramuscular olanzapine for agitated patients: a systematic review and meta-analysis of randomized controlled trials. J Psychiatr Res 68:198–209. https://doi.org/10.1016/j.jpsychires.2015.07.005
Kittipeerachon M, Chaichan W (2016) Intramuscular olanzapine versus intramuscular aripiprazole for the treatment of agitation in patients with schizophrenia: a pragmatic double-blind randomized trial. Schizophr Res 176(2–3):231–238. https://doi.org/10.1016/j.schres.2016.07.017
Kohen I, Preval H, Southard R, Francis A (2005) Naturalistic study of intramuscular ziprasidone versus conventional agents in agitated elderly patients: retrospective findings from a psychiatric emergency service. Am J Geriatr Pharmacother 3(4):240–245
Krakowski MI, Czobor P (2014) Depression and impulsivity as pathways to violence: implications for antiaggressive treatment. Schizophr Bull 40(4):886–894. https://doi.org/10.1093/schbul/sbt117
Kwentus J, Riesenberg RA, Marandi M, Manning RA, Allen MH, Fishman RS et al (2012) Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine. Bipolar Disord 14(1):31–40. https://doi.org/10.1111/j.1399-5618.2011.00975.x
Lavania S, Praharaj SK, Bains HS, Sinha V, Kumar A (2016) Efficacy and safety of levosulpiride versus haloperidol injection in patients with acute psychosis: a randomized double-blind study. Clin Neuropharmacol 39(4):197–200. https://doi.org/10.1097/WNF.0000000000000161
Lehmann P (2015) Psychiatrische Zwangsbehandlung, Menschenrechte und UN-Behindertenrechtskonvention Fragen und Antworten anlässlich der Neufassung des Berliner „Gesetz über Hilfen und Schutzmaβnahmen bei psychischen Krankheiten“ (PsychKG). Recht Psychiatrie 33(1):20–33
Lesem MD, Tran-Johnson TK, Riesenberg RA, Feifel D, Allen MH, Fishman R et al (2011) Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. Br J Psychiatry J Ment Sci 198(1):51–58. https://doi.org/10.1192/bjp.bp.110.081513
Leucht S, Helfer B, Dold M, Kissling W, McGrath J (2014) Carbamazepine for schizophrenia. Cochrane Database Syst Rev (5):CD001258. https://doi.org/10.1002/14651858.CD001258.pub3
Liu CS, Chau SA, Ruthirakuhan M, Lanctot KL, Herrmann N (2015) Cannabinoids for the treatment of agitation and aggression in Alzheimer’s disease. CNS Drugs 29(8):615–623. https://doi.org/10.1007/s40263-015-0270-y
Lonergan E, Luxenberg J, Colford J (2002) Haloperidol for agitation in dementia. Cochrane Database Syst Rev (2):CD002852. https://doi.org/10.1002/14651858.CD002852
Lonergan ET, Cameron M, Luxenberg J (2004) Valproic acid for agitation in dementia. Cochrane Database Syst Rev (2):CD003945. https://doi.org/10.1002/14651858.CD003945.pub2
Lopez OL, Becker JT, Chang Y-F, Sweet RA, Aizenstein H, Snitz B et al (2013) The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer’s disease. Am J Psychiatry 170(9):1051–1058. https://doi.org/10.1176/appi.ajp.2013.12081046
Luaute J, Plantier D, Wiart L, Tell L (2016) Care management of the agitation or aggressiveness crisis in patients with TBI. Systematic review of the literature and practice recommendations. Ann Phys Rehabilitat Med 59(1):58–67. https://doi.org/10.1016/j.rehab.2015.11.001
Maher AR, Maglione M, Bagley S, Suttorp M, Hu J-H, Ewing B et al (2011) Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 306(12):1359–1369. https://doi.org/10.1001/jama.2011.1360
Mann KA, Hoch E, Batra A (2016) S3-Leitlinie Screening, Diagnose und Behandlung Alkoholbezogener Störungen. AWMF-guideline working group (AWMF-Register Nr. 076-001)
Maoz G, Stein D, Meged S, Kurzman L, Levine J, Valevski A et al (2000) The antiaggressive action of combined haloperidol-propranolol treatment in schizophrenia. Eur Psychol 5(4):312
Marder SR, Sorsaburu S, Dunayevich E, Karagianis JL, Dawe IC, Falk DM et al (2010) Case reports of postmarketing adverse event experiences with olanzapine intramuscular treatment in patients with agitation. J Clin Psychiatr 71(4):433–441. https://doi.org/10.4088/JCP.08m04411gry
Marrus N, Underwood-Riordan H, Randall F, Zhang Y, Constantino JN (2014) Lack of effect of risperidone on core autistic symptoms: data from a longitudinal study. J Child Adolesc Psychopharmacol 24(9):513–518. https://doi.org/10.1089/cap.2014.0055
Marschner R (2011) UN-Konvention erfordert ein PsychKG für Bayern. 2. Bayerischen Betreuungsgerichtstag. Bamberg
Marschner R (2013a) Menschen in Krisen: Unterbringung und Zwangsbehandlung in der Psychiatrie. In: Aichele Valentin, Deutsches Institut für Menschenrechte (Hrsg) Das Menschenrecht auf gleiche Recht auf Anerkennung vor dem Recht. Art. 12 der UN-Behindertenrechtskonvention. Nomos, Baden-Baden, S 203–230
Marschner R (2013b) Von der rechtlichen zur sozialen Betreuung – Konsequenzen aus der UN-Behindertenrechtskonvention. Recht Psychiatrie 31:63–70
Marschner R, Volckart B, Lesting W (2010) Freiheitsentziehung und Unterbringung. Materielles Recht und Verfahrensrecht, 5. völlig neu bearbeitete Aufl. C.H.BECK (Beck’sche Kurz-Kommentare, 32), München
Martin V, Steinert T (2005) Ein Vergleich der Unterbringungsgesetze in den 16 deutschen Bundesländern. Krankenhauspsychiatrie 16:2–12
Matson JL, Jang J (2014) Treating aggression in persons with autism spectrum disorders: a review. Res Dev Disabil 35(12):3386–3391. https://doi.org/10.1016/j.ridd.2014.08.025
Mattes JA (1990) Comparative effectiveness of carbamazepine and propranolol for rage outbursts. J Neuropsychiatr Clin Neurosci 2(2):159–164. https://doi.org/10.1176/jnp.2.2.159
McDougle CJ, Naylor ST, Cohen DJ, Volkmar FR, Heninger GR, Price LH (1996) A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 53(11):1001–1008
McDougle CJ, Holmes JP, Carlson DC, Pelton GH, Cohen DJ, Price LH (1998) A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry 55(7):633–641
McMurran M, Huband N, Overton E (2010) Non-completion of personality disorder treatments: a systematic review of correlates, consequences, and interventions. Clin Psychol Rev 30(3):277–287. https://doi.org/10.1016/j.cpr.2009.12.002
Mendez Juan E, Vereinte Nationen (2013) Report of the special rapporteur on torture and other cruel, inhuman or degrading treatment or punishment. Human Rights Council, 22nd session. https://documents-dds-ny.un.org/doc/UNDOC/GEN/G13/105/77/PDF/G1310577.pdf?OpenElement. Zugegriffen am 01.12.2017
Mercer D, Douglass AB, Links PS (2009) Meta-analyses of mood stabilizers, antidepressants and antipsychotics in the treatment of borderline personality disorder: effectiveness for depression and anger symptoms. J Personal Disord 23(2):156–174. https://doi.org/10.1521/pedi.2009.23.2.156
Meyer JM (2014) A rational approach to employing high plasma levels of antipsychotics for violence associated with schizophrenia: case vignettes. CNS spectrums 19(5):432–438. https://doi.org/10.1017/S1092852914000236
Mittag M (2012) Die verfassungsrechtlichen Anforderungen an psychiatrische Zwangsbehandlungen im Betreuungsrecht. Recht Psychiatrie 30:197–205
Mittag (2014) Die betreuungsrechtliche Zwangsbehandlung im Lichte ihrer Neuregelung. In: Henking, Vollmann J (Hrsg) Gewalt und Psyche – Die Zwangsbehandlung auf dem Prüfstand: Nomos, Baden-Baden
Morrissette DA, Stahl SM (2014) Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy. CNS spectrums 19(5):439–448. https://doi.org/10.1017/S1092852914000388
National Institute for Health and Care Excellence (NICE) (Hrsg) (2015) Violence and aggression: short-term management in mental health, health and community settings: updated edition. British Psychological Society, London
van Noord C, Straus SMJM, Sturkenboom MCJM, Hofman A, Aarnoudse A-JLHJ, Bagnardi V et al (2009) Psychotropic drugs associated with corrected QT interval prolongation. J Clin Psychopharmacol 29(1):9–15. https://doi.org/10.1097/JCP.0b013e318191c6a8
Nurenberg JR, Schleifer SJ, Shaffer TM, Yellin M, Desai PJ, Amin R et al (2015) Animal-assisted therapy with chronic psychiatric inpatients: equine-assisted psychotherapy and aggressive behavior. Psychiatr Serv (Washington DC) 66(1):80–86. https://doi.org/10.1176/appi.ps.201300524
Olin JT, Fox LS, Pawluczyk S, Taggart NA, Schneider LS (2001) A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease. Am J Geriatric Psychiatry Off J Am Assoc Geriatric Psychiatry 9(4):400–405
Olzen D (2017) Die Auswirkungen des Betreuungsrechtsänderungsgesetzes (Patientenverfügungsgesetz) auf die medizinische Versorgung psychisch Kranker. Gutachten im Auftrag der DGPPN. https://www.dgppn.de/fileadmin/user_upload/_medien/download/pdf/stellungnahmen/2010/stn-2010-04-15-anh-gutachten-prof-olzen-pat-vg.pdf. Zugegriffen am 01.12.2017
Pascual JC, Madre M, Soler J, Barrachina J, Campins MJ, Alvarez E, Perez V (2006) Injectable atypical antipsychotics for agitation in borderline personality disorder. Pharmacopsychiatry 39(3):117–118. https://doi.org/10.1055/s-2006-941489
Penders TM, Gestring RE, Vilensky DA (2012) Excited delirium following use of synthetic cathinones (bath salts). Gen Hosp Psychiatry 34(6):647–650. https://doi.org/10.1016/j.genhosppsych.2012.06.005
Plantier D, Luaute J (2016) Drugs for behavior disorders after traumatic brain injury: systematic review and expert consensus leading to French recommendations for good practice. Ann Phys Rehabilitat Med 59(1):42–57. https://doi.org/10.1016/j.rehab.2015.10.003
Pollmächer T (2013) Ordnungspolitische Funktion der Psychiatrie – Kontra. Psychiatr Prax 40(06):305–306. https://doi.org/10.1055/s-0033-1343217
Pollmächer T (2015) Moral oder Doppelmoral? Das Berufsethos des Psychiaters im Spannungsfeld zwischen Selbstbestimmung, Rechten Dritter und Zwangsbehandlung. Nervenarzt 86(9):1148–1156
Pollmächer T (2016) Gefährdung Dritter als Rechtfertigung einer öffentlich-rechtlichen Unterbringung psychisch Kranker Pro & Kontra. Psychiatr Prax 43:11–12
Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z et al (2014) Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA 311(7):682–691. https://doi.org/10.1001/jama.2014.93
Powney MJ, Adams CE, Jones H (2012) Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation). Cochrane Database Syst Rev 11:CD009377. https://doi.org/10.1002/14651858.CD009377.pub2
Pratts M, Citrome L, Grant W, Leso L, Opler LA (2014) A single-dose, randomized, double-blind, placebo-controlled trial of sublingual asenapine for acute agitation. Acta Psychiatr Scand 130(1):61–68. https://doi.org/10.1111/acps.12262
Rampling J, Furtado V, Winsper C, Marwaha S, Lucca G, Livanou M, Singh SP (2016) Non-pharmacological interventions for reducing aggression and violence in serious mental illness: a systematic review and narrative synthesis. Eur Psychiatr J Assoc Eur Psychiatr 34:17–28. https://doi.org/10.1016/j.eurpsy.2016.01.2422
Ripoll LH (2013) Psychopharmacologic treatment of borderline personality disorder. Dialogues Clin Neurosci 15(2):213–224
Roberts R, MacDougall NJJ, O’Brien P, Abdelaziz K, Christie J, Swingler R (2012) Not hysteria: ovarian teratoma-associated anti-N-methyl-D-aspartate receptor encephalitis. Scott Med J 57(3):182. https://doi.org/10.1258/smj.2012.012026
Rosenbluth M, Sinyor M (2012) Off-label use of atypical antipsychotics in personality disorders. Expert Opin Pharmacother 13(11):1575–1585. https://doi.org/10.1517/14656566.2011.608351
Rosenow R (2013) Betreuungsrechtliche Unterbringung und Zwangsbehandlung vor dem Hintergrund der UN-BRK. Betreuungsrechtliche Praxis 22:39–44
Schalast N (2016) Gefährdung Dritter als Rechtfertigung einer öffentlich-rechtlichen Unterbringung psychisch Kranker? – Pro. Psychiatr Prax 43(01):10–11
Schmahl S (2016) Menschenrechtliche Sicht auf die Zwangsbehandlung von Erwachsenen bei Selbstgefährdung. Betreuungsrechtliche Praxis 25:51–54
Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS (2007) Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ Can Med Assoc J J de l’Association medicale canadienne 176(5):627–632. https://doi.org/10.1503/cmaj.061250
Schofield PW, Malacova E, Preen DB, D’Este C, Tate R, Reekie J et al (2015) Does traumatic brain injury lead to criminality? A whole-population retrospective cohort study using linked data. PLoS One 10(7):e0132558. https://doi.org/10.1371/journal.pone.0132558
Seitz DP, Adunuri N, Gill SS, Gruneir A, Herrmann N, Rochon P (2011) Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev (2):CD008191. https://doi.org/10.1002/14651858.CD008191.pub2
Smith EN, Durge V, Sengupta S, Das M (2014) Asenapine augmentation and treatment-resistant schizophrenia in the high-secure hospital setting. Therapeut Adv Psychopharmacol 4(5):193–197. https://doi.org/10.1177/2045125314537866
Snellgrove B, Steinert T (2017) Einwilligungsfähigkeit vor dem Hintergrund der UN-Behindertenrechtskonvention. Forens Psychiatr Psychol Kriminol. https://doi.org/10.1007/s11757-017-0427-2
Sochocky N, Milin R (2013) Second generation antipsychotics in Asperger’s disorder and high functioning autism: a systematic review of the literature and effectiveness of meta-analysis. Curr Clin Pharmacol 8(4):370–379
Sohanpal SK, Deb S, Thomas C, Soni R, Lenotre L, Unwin G (2007) The effectiveness of antidepressant medication in the management of behaviour problems in adults with intellectual disabilities: a systematic review. J Intellect Disabil Res JIDR 51(Pt 10):750–765. https://doi.org/10.1111/j.1365-2788.2006.00935.x
Sommer OH, Aga O, Cvancarova M, Olsen IC, Selbaek G, Engedal K (2009) Effect of oxcarbazepine in the treatment of agitation and aggression in severe dementia. Dement Geriatr Cogn Disord 27(2):155–163. https://doi.org/10.1159/000199236
Spickhoff A (2014) Medizinrecht, 2. Aufl. C.H. BECK (Beck’sche Kurz-Kommentare, München
Steinert T (2014a) Missbrauch der Psychiatrie. Psychiatr Prax 41:237–238
Steinert T (2015) Zwangsmaßnahmen aus der Perspektive der klinischen Psychiatrie: Evidenz und Good Clinical Practice. In: Henking T, Vollmann J (Hrsg) Zwangsbehandlung psychisch kranker Menschen – Ein Leitfaden für die Praxis. Springer, Berlin, S 1–18
Steinert T (2017a) Ethics of coercive treatment and misuse of psychiatry. Psychiatr Serv (Washington DC) 68(3):291–294. https://doi.org/10.1176/appi.ps.201600066
Steinert T (2017b) Patientenautonomie ernst nehmen. Psychiatr Prax 44:122–124
Steinert T, Hamann K (2012) External validity of studies on aggressive behavior in patients with schizophrenia: systematic review. Clin Prac Epidemiol Mental Health CP & EMH 8:74–80. https://doi.org/10.2174/1745017901208010074
Steinert T, Kallert TW (2006) Medikamentöse Zwangsbehandlung in der Psychiatrie. Psychiatr Prax 33:160–169
Steinert T, Sippach T, Gebhardt RP (2000) How common is violence in schizophrenia despite neuroleptic treatment? Pharmacopsychiatry 33(3):98–102. https://doi.org/10.1055/s-2000-342
Steinert C, Steinert T, Flammer E, Jaeger S (2016) Impact of the UN convention on the rights of persons with disabilities (UN-CRPD) on mental health care research – a systematic review. BMC Psychiatr 16:166
Stoffers J, Vollm BA, Rucker G, Timmer A, Huband N, Lieb K (2010) Pharmacological interventions for borderline personality disorder. Cochrane Database Syst Rev (6):CD005653. https://doi.org/10.1002/14651858.CD005653.pub2
Sultana J, Chang CK, Hayes RD, Broadbent M, Stewart R, Corbett A, Ballard C (2014) Associations between risk of mortality and atypical antipsychotic use in vascular dementia: a clinical cohort study. Int J Geriatr Psychiatr 29(12):1249–1254. https://doi.org/10.1002/gps.4101
Swanson JW, Swartz MS, Elbogen EB, van Dorn RA (2004) Reducing violence risk in persons with schizophrenia: olanzapine versus risperidone. J Clin Psychiatr 65(12):1666–1673
Swanson JW, Swartz MS, van Dorn RA, Volavka J, Monahan J, Stroup TS et al (2008) Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. Br J Psychiatr J Mental Sci 193(1):37–43. https://doi.org/10.1192/bjp.bp.107.042630
Tariot PN, Erb R, Podgorski CA, Cox C, Patel S, Jakimovich L, Irvine C (1998) Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 155(1):54–61. https://doi.org/10.1176/ajp.155.1.54
Tolisano P, Sondik TM, Dike CC (2017) A positive behavioral approach for aggression in forensic psychiatric settings. J Am Acad Psychiatr Law 45(1):31–39
Topiwala A, Fazel S (2011) The pharmacological management of violence in schizophrenia: a structured review. Expert Rev Neurother 11(1):53–63. https://doi.org/10.1586/ern.10.180
Tran-Johnson TK, Sack DA, Marcus RN, Auby P, McQuade RD, Oren DA (2007) Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatr 68(1):111–119
Tsiouris JA (2010) Pharmacotherapy for aggressive behaviours in persons with intellectual disabilities: treatment or mistreatment? J Intellect Disabil Res JIDR 54(1):1–16. https://doi.org/10.1111/j.1365-2788.2009.01232.x
Tyrer P, Oliver-Africano PC, Ahmed Z, Bouras N, Cooray S, Deb S et al (2008) Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial. Lancet (London) 371(9606):57–63. https://doi.org/10.1016/S0140-6736(08)60072-0
Ujkaj M, Davidoff DA, Seiner SJ, Ellison JM, Harper DG, Forester BP (2012) Safety and efficacy of electroconvulsive therapy for the treatment of agitation and aggression in patients with dementia. Am J Geriatr Psychiatry 20(1):61–72
Valentin A (2013) Einleitung. In: Valentin A, Deutsches Institut für Menschenrechte (Hrsg) Das Menschenrecht auf gleiche Recht auf Anerkennung vor dem Recht. Art. 12 der UN-Behindertenrechtskonvention. Nomos, Baden-Baden, S 13–34
Valentin A, Deutsches Institut für Menschenrechte (Hrsg) (2013) Das Menschenrecht auf gleiche Recht auf Anerkennung vor dem Recht. Art. 12 der UN-Behindertenrechtskonvention. Nomos, Baden-Baden
Vereinte Nationen (2014) Behindertenrechtskonvention und Allgemeiner Kommentar Nr. 1. Zuletzt geprüft am 01.12.2017
Verhey FRJ, Verkaaik M, Lousberg R (2006) Olanzapine versus haloperidol in the treatment of agitation in elderly patients with dementia: results of a randomized controlled double-blind trial. Dement Geriatr Cogn Disord 21(1):1–8. https://doi.org/10.1159/000089136
Volavka J (2013) Violence in schizophrenia and bipolar disorder. Psychiatr Danub 25(1):24–33
Vollmann J (2008) Patientenselbstbestimmung und Selbstbestimmungsfähigkeit: Beiträge zur Klinischen Ethik. Kohlhammer, Stuttgart
Vollmann J (2014) Zwangsbehandlungen in der Psychiatrie. Eine ethische Analyse der neuen Rechtslage für die klinische Praxis 5:614–620
Wahlbeck K, Cheine MV, Gilbody S, Ahonen J (2000) Efficacy of beta-blocker supplementation for schizophrenia: a systematic review of randomized trials. Schizophr Res 41(2):341–347
Walther S, Moggi F, Horn H, Moskvitin K, Abderhalden C, Maier N et al (2014) Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine. J Clin Psychopharmacol 34(1):124–128. https://doi.org/10.1097/JCP.0000000000000050
Wang LY, Shofer JB, Rohde K, Hart KL, Hoff DJ, McFall YH et al (2009) Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression. Am J Geriatric Psychiatry Off J Am Assoc Geriatric Psychiatry 17(9):744–751. https://doi.org/10.1097/JGP.0b013e3181ab8c61
Wang Y, Xia J, Helfer B, Li C, Leucht S (2016) Valproate for schizophrenia. Cochrane Database Syst Rev 11:CD004028. https://doi.org/10.1002/14651858.CD004028.pub4
Ward F, Tharian P, Roy M, Deb S, Unwin GL (2013) Efficacy of beta blockers in the management of problem behaviours in people with intellectual disabilities: a systematic review. Res Dev Disabil 34(12):4293–4303. https://doi.org/10.1016/j.ridd.2013.08.015
Weig W, Cording C (Hrsg) (2003) Zwischen Zwang und Fürsorge – die Psychiatriegesetze der deutschen Länder. Deutscher Wissenschafts, Würzburg/Baden-Baden
Wilcock GK, Ballard CG, Cooper JA, Loft H (2008) Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer’s disease: a pooled analysis of 3 studies. J Clin Psychiatr 69(3):341–348
Williams K, Brignell A, Randall M, Silove N, Hazell P (2013) Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database Syst Rev (8):CD004677. https://doi.org/10.1002/14651858.CD004677.pub3
Wilson MP, MacDonald K, Vilke GM, Feifel D (2012) A comparison of the safety of olanzapine and haloperidol in combination with benzodiazepines in emergency department patients with acute agitation. J Emerg Med 43(5):790–797. https://doi.org/10.1016/j.jemermed.2011.01.024
Wink LK, Pedapati EV, Horn PS, McDougle CJ, Erickson CA (2017) Multiple antipsychotic medication use in autism spectrum disorder. J Child Adolesc Psychopharmacol 27(1):91–94. https://doi.org/10.1089/cap.2015.0123
Witt K, van Dorn R, Fazel S (2013) Risk factors for violence in psychosis: systematic review and meta-regression analysis of 110 studies. PLoS One 8(2):e55942. https://doi.org/10.1371/journal.pone.0055942
Woodward MR, Harper DG, Stolyar A, Forester BP, Ellison JM (2014) Dronabinol for the treatment of agitation and aggressive behavior in acutely hospitalized severely demented patients with noncognitive behavioral symptoms. Am J Geriatr Psychiatr Off J Am Assoc Geriatric Psychiatry 22(4):415–419. https://doi.org/10.1016/j.jagp.2012.11.022
Yeh Y-C, Ouyang W-C (2012) Mood stabilizers for the treatment of behavioral and psychological symptoms of dementia: an update review. Kaohsiung J Med Sci 28(4):185–193. https://doi.org/10.1016/j.kjms.2011.10.025
Zanarini MC, Schulz SC, Detke HC, Tanaka Y, Zhao F, Lin D et al (2011) A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study. J Clin Psychiatr 72(10):1353–1362. https://doi.org/10.4088/JCP.08m04138yel
Zentrale Ethikkommission zur Wahrung ethischer Grundsätze in der Medizin und ihren Grenzgebieten bei der Ärztekammer (ZEKO 2013) (2013) Stellungnahme Zwangsbehandlung bei psychischen Erkrankungen. Dtsch Ärztebl 26:A1334–A1338
Zimbroff DL, Marcus RN, Manos G, Stock E, McQuade RD, Auby P, Oren DA (2007) Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole. J Clin Psychopharmacol 27(2):171–176. https://doi.org/10.1097/JCP.0b13e318033bd5e
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 DGPPN (Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde)
About this chapter
Cite this chapter
Steinert, T., Hirsch, S. (2019). Intervention. In: Steinert, T., Hirsch, S. (eds) S3-Leitlinie Verhinderung von Zwang: Prävention und Therapie aggressiven Verhaltens bei Erwachsenen. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-58684-6_12
Download citation
DOI: https://doi.org/10.1007/978-3-662-58684-6_12
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-58683-9
Online ISBN: 978-3-662-58684-6
eBook Packages: Medicine (German Language)